Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
Argus Health
Teva
Daiichi Sankyo
McKesson
Cantor Fitzgerald
Harvard Business School
Julphar
McKinsey

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,501,698

« Back to Dashboard

Summary for Patent: 8,501,698
Title:Crystal structures of SGLT2 inhibitors and processes for preparing same
Abstract: The present invention relates to physical crystal structures of a compound of the formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.2a, R.sup.3 and R.sup.4 are as defined herein, especially ##STR00002## pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
Inventor(s): Gougoutas; Jack Z. (Princeton, NJ), Lobinger; Hildegard (Princeton, NJ), Ramakrishnan; Srividya (Princeton, NJ), Deshpande; Prashant P. (Princeton, NJ), Bien; Jeffrey T. (Princeton, NJ), Lai; Chiajen (Princeton, NJ), Wang; Chenchi (Princeton, NJ), Riebel; Peter (Princeton, NJ), Grosso; John Anthony (Princeton, NJ), Nirschl; Alexandra A. (Princeton, NJ), Singh; Janak (Princeton, NJ), DiMarco; John D. (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/049,712
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,501,698

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-005 Jul 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-002 Oct 29, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-004 Oct 29, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-003 Oct 29, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Sign Up
Astrazeneca Ab QTERN dapagliflozin propanediol; saxagliptin hydrochloride TABLET;ORAL 209091-001 Feb 27, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,501,698

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,919,598 Crystal structures of SGLT2 inhibitors and processes for preparing same ➤ Sign Up
9,453,039 Crystal structures of SGLT2 inhibitors and processes for preparing same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,501,698

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia 53638 ➤ Sign Up
Portugal 2069374 ➤ Sign Up
Philippines 12012500168 ➤ Sign Up
Peru 07762012 ➤ Sign Up
Peru 03492008 ➤ Sign Up
New Zealand 589202 ➤ Sign Up
New Zealand 589195 ➤ Sign Up
New Zealand 589190 ➤ Sign Up
New Zealand 574346 ➤ Sign Up
Norway 20085169 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Fuji
Healthtrust
AstraZeneca
Julphar
QuintilesIMS
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot